Citations

Clear

4510 citation(s) found for "Scott, C".

Does smoking status affect baseline symptom severity and patient-reported outcomes and satisfaction in patients with cervical myelopathy at 24 months? A Quality Outcomes Database study
Park, Christine , Bhowmick, Deb A. , Shaffrey, Christopher I., Johnson, Sarah E. , Bisson, Erica F. , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Schüpper, Alexander J. , Tumialán, Luis M. , Turner, Jay D. , Chan, Andrew K. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Bydon, Mohamad , Gottfried, Oren N., Shaffrey, Christopher I. , Lavadi, Raj Swaroop , Park, Paul , Fu, Kai-Ming, Uribe, Juan S. , Mummaneni, Praveen V.

Mayo Clinic

Journal of Neurosurgery: Spine | February 14, 2025 | Volume: 42 | Issue: 5 | Pages: 533-540

10.3171/2024.10.spine24744 | PMID 39951720 Get It

OBJECTIVE It is not clear whether smoking impacts patient-reported outcomes (PROs) in patients with cervical spondylotic myelopathy (CSM). The aim of this study was to explore the impact of smoking status on baseline symptom severity and the rate of achieving satisfaction and the minimal clinically important differences (MCIDs) for PROs in patients with CSM. METHODS This study was an analysis of the prospective Quality Outcomes Database CSM module. Patients aged ≥ 18 years diagnosed with primary CSM who underwent elective surgery were included. PROs (visual analog scale [VAS] neck and arm pain, Neck Disability Index [NDI], modified Japanese Orthopaedic Association [mJOA], and EQ-5D scores and North American Spine Society [NASS] patient satisfaction) were collected at baseline and 24 months of follow-up. RESULTS Of the 1141 patients with CSM, 202 (17.7%) were smokers and 939 (82.3%) were nonsmokers. Compared with the nonsmokers, smokers were younger (56.3 ± 11.3 years vs 61.5 ± 11.7 years, p < 0.01) and had a lower BMI (29.3 ± 6.8 vs 30.3 ± 6.3, p = 0.04). A higher proportion of smokers had depression, anxiety, and chronic obstructive pulmonary disease (all p < 0.01). At baseline, smokers had worse pain (VAS neck pain score: 6.0 ± 3.2 vs 5.1 ± 3.3; VAS arm pain score: 5.7 ± 3.2 vs 4.7 ± 3.5), disability (NDI score: 45.2 ± 20.0 vs 37.1 ± 20.6), myelopathy (mJOA score: 11.5 ± 2.9 vs 12.2 ± 2.8), and quality of life (EQ-5D score: 0.51 ± 0.23 vs 0.57 ± 0.22) (all p < 0.01). At the 24-month follow-up, a higher proportion of smokers achieved the MCID in mJOA (69.4% vs 56.6%, p < 0.01) compared with nonsmokers. However, after accounting for significant covariates, there was no significant difference in the baseline disease severity. There was also no difference between the PROs at the 24-month follow-up. The two groups also achieved similar MCIDs for most PROs and were similarly satisfied (NASS score of 1 or 2: smoker 81.2% vs nonsmoker 84.6%, p = 0.29) 24 months after surgery. CONCLUSIONS Smokers and nonsmokers with CSM had similar baseline disease severity and 24-month PROs. They also achieved similar rates of MCIDs for PROs and satisfaction after surgery. Numerous previous studies have documented the association between tobacco usage and inferior clinical outcomes after spine surgery. However, in the context of severe and debilitating spinal disorders such as cervical myelopathy, meaningful and impactful improvements are still seen in properly selected patients.
Physics‐informed model‐based generative neural network for synthesizing scanner‐ and algorithm‐specific low‐dose CT exams
Yu, Lifeng , Hsieh, Scott S. , Gong, Hao , Yu, Lifeng , Leng, Shuai , Fletcher, Joel G. , McCollough, Cynthia H.

Mayo Clinic

Medical Physics | February 13, 2025 | Volume: 52 | Issue: 6 | Pages: 3940-3958

10.1002/mp.17680 | PMID 39945452 Get It

Abstract Background Accurate low‐dose CT simulation is required to efficiently assess reconstruction and dose reduction techniques. Projection domain noise insertion requires proprietary information from manufacturers. Analytic image domain noise insertion methods are successful for linear reconstruction algorithms, however extending them to non‐linear algorithms remains challenging. Emerging, deep‐learning‐based image domain noise insertion methods have potential, but few approaches have explicitly incorporated physics information and a texture‐synthesis model to guide the generation of locally and globally correlated noise texture. Purpose We proposed a p hysics‐informed model‐based gener a tive neura l network for simulating scann e r‐ and algori t hm‐specific low‐dose C T e xams (PALETTE). It is expected to provide an alternative to projection domain noise insertion methods in the absence of manufacturers’ proprietary information and tools. Methods PALETTE integrated a physics‐based noise prior generation process, a Noise2Noisier sub‐network, and a noise texture synthesis sub‐network. The Noise2Noisier sub‐network provided a bias prior, which, combined with the noise prior, served as the inputs to noise texture synthesis sub‐network. Explicit regularizations in spatial and frequency domains were developed to account for noise spatial correlation and frequency characteristics. For proof‐of‐concept, PALETTE was trained and validated for a commercial iterative reconstruction algorithm (SAFIRE, Siemens Healthineers), using the paired routine and 25% dose images from CT phantoms (lateral size 30–40 cm; three training and four testing phantoms) and open‐access patient cases (10 training and 20 testing cases). In phantom validation, noise power spectra (NPS) were compared in water background and tissue‐mimicking inserts, using peak frequency and mean‐absolute‐error (MAE). In patient case evaluation, visual inspection and quantitative assessment were conducted on axial, coronal, and sagittal planes. Local and global noise texture were visually inspected in low‐dose CT images and the difference images between routine and low dose. Noise levels in liver and fat were measured. Local and global 2D Fourier magnitude spectra of the difference images and the corresponding radial mean profiles were used to assess similarity in noise frequency components within tissues and entire field‐of‐view, using spectral correlation mapper (SCM) and spectral angle mapper (SAM). Several baseline neural network models (e.g., GAN) were included in the evaluation. Statistical significance was tested using a t ‐test for related samples. Results PALETTE‐derived NPS showed accurate noise peak frequency (PALETTE/reference: water 1.40/1.40 lp/cm; inserts 1.7/1.7lp/cm) and small MAE (≤0.65 HU 2 cm 2 ). PALETTE created anatomy‐dependent noise texture, showing realistic local and global granularity and streaks. No statistically significant difference was observed in noise levels ( p > 0.05). Noise range was comparable across 3D image volume (PALETTE / reference):liver – [18.0, 53.4] / [19.3, 50.0] HU; fat – [11.7, 42.4] / [12.1, 41.3] HU. Percent absolute difference of local noise was small (mean ± standard deviation): liver 4.1%±3.1%, fat 4.6%±3.1%. Noise frequency distribution was close to the reference (mean per case): SCM ≥ 0.92, SAM ≤ 0.22. Additionally, PALETTE outperformed all baseline models in visual inspection and quantitative comparison. Conclusion PALETTE can provide high‐quality image domain noise insertion for simulating accurate low‐dose CT images created with a commercial non‐linear reconstruction algorithm.
Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET
Przybelski, Scott A. , Wiste, Heather J. , Fought, Angela J. , Jack, Clifford R. , Lowe, Val J. , Petersen, Ronald C. , Kantarci, Kejal , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Kantarci, Kejal , Mak, Elijah , Schwarz, Christopher G. , Senjem, Matthew L. , Boeve, Bradley F. , O'Brien, John Tiernan , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | February 12, 2025 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14571 | PMID 39935389 Get It

Abstract INTRODUCTION We investigated the association between alpha‐synuclein (α‐syn) pathology and brain glucose metabolism across the cognitive spectrum of Alzheimer's disease (AD) co‐pathologies. METHODS Fluorodeoxyglucose positron emission tomography (FDG‐PET) data from 829 Alzheimer's Disease Neuroimaging Initiative participants (648 cognitively impaired [CI], 181 unimpaired [CU]) were compared between α‐syn seed amplification assay (SAA) positive and negative groups. Interactions with cerebrospinal fluid (CSF) AD biomarkers were examined. RESULTS SAA+ was associated with widespread hypometabolism among CI individuals, particularly in posterior cortical regions, independent of CSF amyloid and tau levels in the occipital lobes. Regional hypometabolism mediated the effect of α‐syn SAA on disease severity in CI individuals, independent of CSF amyloid and tau levels. There were no influences of SAA on FDG‐PET in CU individuals. DISCUSSION This study supports a model in which α‐syn aggregation influences metabolic dysfunction, which then influences clinical disease severity, independent of AD. SAA+ could help optimize participant selection and outcome measures for clinical trials in AD. Highlights α‐synuclein seed amplification positivity (SAA+) was associated with hypometabolism in cognitively impaired individuals. Hypometabolism mediated the influence of α‐synuclein on disease severity. Occipital hypometabolism in SAA+ was independent of cerebrospinal fluid levels of Alzheimer's disease pathology. These findings can optimize future clinical trials targeting α‐synuclein pathology.
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
Pazo-Cid, Roberto , Chandana, Sreenivasa R , Dean, Andrew, Leei, Woo Jin, Goetze, Thorsten Oliver , Paulson, Andrew Scott , Bekaii‐Saab, Tanios , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Chen, Huanyu , Benzaghou, Fawzi, Bekaii-Saab, Tanios S , Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Future Oncology | February 12, 2025 | Volume: 21 | Issue: 7 | Pages: 765-774

10.1080/14796694.2025.2458458 | PMID 39935331 Get It

Therapeutic left-to-right shunting in heart failure
Fioretti, Francesco , Anker, Stefan D. , Borlaug, Barry A. , Kereiakes, Dean J. , Lindenfeld, JoAnn , Stone, Gregg W. , Butler, Javed , Nair, Ajith P , Anker, Stefan D , Borlaug, Barry A , Kereiakes, Dean J , Lindenfeld, JoAnn , Stone, Gregg W , Butler, Javed , Nair, Ajith

Mayo Clinic

European Heart Journal | February 11, 2025 | Volume: 46 | Issue: 19 | Pages: 1787-1802

10.1093/eurheartj/ehaf120 | PMID 39943738 Get It

Abstract Heart failure with reduced or preserved ejection fraction is associated with elevated left atrial pressure at rest due to fluid overload or during exercise, leading to pulmonary venous congestion. Even with available treatments, heart failure hospitalizations remain high, and improvements in quality-of-life scores and functional capacity are modest. Thus, there is growing interest in non-pharmacological methods to decompress the left atrium and improve heart failure symptoms and outcomes. Left-to-right shunts have emerged as a potential therapeutic option to reduce left atrial hypertension, improve quality of life, and impact long-term outcomes. This nascent field carries both potential therapeutic promise and many unanswered questions. Recent data have questioned whether the effects of this therapy vary based on the left ventricular ejection fraction, pulmonary vascular resistance, and/or right ventricular structure and function. This review discusses the basis for left-to-right shunt therapies, synthesizes past and ongoing clinical trials, and offers future directions.
Symposia Report of The Annual Biological Sciences Section Meeting of the Gerontological Society of America 2023, Tampa, Florida
Rogina, Blanka , Anderson, Rozalyn M. , Curan, Sean, Yousefzadeh, Matthew J. , Ghosh, Bhaswati, Duque, Gustavo , Howlett, Susan E. , Austad, Steven N. , Korfhage, Justin , Christensen, Kaare , Carey, James R. , Bell, Justice, Gomes, Ana P. , Dixit, Vishwa Deep , Sen, Payel , Imai, Shin‐ichiro , Valdez, Gregorio , Orr, Miranda E. , Jones, Leanne , Castillo-Azofeida, David, Bonaguidi, Michael A. , Suh, Yousin , Duncan, Francesca E. , C, Weigler G Perry, Burkewitz, Kristopher , Zhou, Kai , Bouhrara, Mustapha , Kolind, Shannon , Dean, Doug, Pálovics, Róbert , Niedernhofer, Laura J. , Fan, Rong , Bueckle, Andreas , Kapahi, Pankaj , Jiang, Nisi , Diaz, Jose , Mishra, Sidharth P. , Ralmundo, Nuno, Banarjee, Reema , Allsopp, Richard , Curran, Sean P. , Anderson, Rozalyn M , Curran, Sean P , Yousefzadeh, Matthew J , Duque, Gustavo , Howlett, Susan , Austad, Steven , Demuth, Ilja , Gerstorf, Denis , Abadir, Peter , Christensen, Kaare , Palmer, Allyson, Basisty, Nathan , de Cabo, Rafael , Sen, Payel , Baur, Joseph A , Duncan, Francesca E , Benjamini, Dan , Walker, Keenan A , Dean, Douglas C , Gladyshev, Vadim N , Fan, Rong , Sato, Shogo , Jiang, Nisi , Ashiqueali, Sarah A., Allsopp, Richard , Niedernhofer, Laura J , Kollind, Shannon H , LeBrasseur, Nathan K. , Lombard, David B. , Alberts, Susan C. , Campos, Fernando A. , Palavicini, Juan Pablo , Palmer, Allyson K. , Basisty, Nathan , Cabo, Rafael de , Baur, Joseph A. , Li, Xiaoling , Pletcher, Scott D. , Andersen, Julie Kay , Jones, Leanne, Suh, Yousin , Murray, Anna , Wang, Meng C., Henne, W. Mike , Walker, Keenan A. , Reiter, David A. , Gorbunova, Vera , Gladyshev, Vadim N. , Hurley, Jennifer , Esser, Karyn A. , Ashiqueali, Sarah , Reynolds, Lindsay M. , Zhang, Bohan , Sebastiani, Paola , Monti, Stefano , Schork, Nicholas J. , Rappaport, Noa

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | February 11, 2025 | Volume: 80 | Issue: 5 | Pages: No page available

10.1093/gerona/glaf026 | PMID 39932386 Get It

Abstract The aging process is universal, and it is characterized by a progressive deterioration and decrease in physiological function leading to decline on the organismal level. Nevertheless, a number of genetic and nongenetic interventions have been described, which successfully extend healthspan and lifespan in different species. Furthermore, a number of clinical trials have been evaluating the feasibility of different interventions to promote human health. The goal of the annual Biological Sciences Section of the Gerontological Society of America meeting was to share current knowledge of different topics in aging research and provide a vision of the future of aging research. The meeting gathered international experts in diverse areas of aging research including basic biology, demography, and clinical and translational studies. Specific topics included metabolism, inflammaging, epigenetic clocks, frailty, senescence, neuroscience, stem cells, reproductive aging, inter-organelle crosstalk, comparative transcriptomics of longevity, circadian clock, metabolomics, and biodemography.
Late Sustained Ventricular Arrhythmias After Left Ventricular Assist Device Implantation: Outcomes and Predictors
Karikalan, Suganya Arunachalam , Lee, Justin Z. , Zhang, Nan , Killu, Ammar M. , Deshmukh, Abhishek , Sorajja, Dan , El‐Masry, Hicham, Mulpuru, Siva K. , Cha, Yong‐Mei , Scott, Luis, Masry, Hicham El , Karikalan, Suganya , Tan, Min Choon , Killu, Ammar M , El-Masry, Hicham, Cha, Yong-Mei , El Masry, Hicham , McLeod, Christopher J.

Mayo Clinic

Pacing and Clinical Electrophysiology | February 11, 2025 | Volume: 48 | Issue: 4 | Pages: 386-393

10.1111/pace.15158 | PMID 39925318 Get It

ABSTRACTBackgroundThe factors contributing to sustained ventricular arrhythmias (VAs) >30 days after left ventricular assist device (LVAD) implantation are not well‐established.ObjectivesThis study aimed to predict the factors associated with late sustained VAs after LVAD implantation and develop a predictive score to identify patients with an increased risk of late sustained VAs after the procedure.MethodsWe performed a retrospective cohort study on a training cohort of 623 patients and a validation cohort of 157 patients who underwent LVAD implantation at the Mayo Clinic (Rochester, Phoenix, and Jacksonville) from January 1, 2000, to December 30, 2020. Late sustained VAs were defined as ventricular tachycardia (VT) and ventricular fibrillation (VF) occurring >30 days after the LVAD procedure. Detailed chart reviews of the electronic health records within the Mayo Clinic and outside medical records were performed.ResultsA total of 780 patients were included in our study. Late sustained VAs occurred in 30% (n = 232) of the patients. The significant factors associated with late sustained VAs after LVAD were the history of VAs prior to LVAD (34.1% vs. 23.0%, p < 0.01), implantable cardiac defibrillator (ICD) (87.9% vs. 77.6%, p < 0.01) or cardiac resynchronization therapy (CRT) in situ (43.5% vs. 33.6%, p = 0.008), VT ablation prior to LVAD (5.2% vs. 1.8%, p = 0.010), use of amiodarone (49.1% vs. 38.7%, p = 0.007), use of mexiletine (15.5% vs. 5.7%, p < 0.01), and higher left ventricular end‐diastolic diameter (LVEDD) on echocardiography prior to LVAD implantation (71.4 vs. 68.7 mm, p = 0.002). During follow‐up, the patients who developed late sustained VAs after LVAD had lower survival than those who did not (HR = 1.96, 95% CI:156–2.4, p < 0.001). The average time from LVAD to orthotopic heart transplant was longer among late sustained VAs patients (23 vs. 14 months, p < 0.01). The “VIN” risk score was created to identify four risk groups: low (scores 0), intermediate (score 1), high (score 2), and very high (score 3). The rates of late VA's in the training cohort at 1 year were 9.5%, 14%, 18%, and 25% which was almost similar to the risk of late VA's at validation cohort 10%, 12%, 20%, and 63%, respectively.ConclusionsLate sustained VAs occurred in 30% of the patients who received LVAD and were associated with lower survival. The VIN risk score was developed and validated to stratify patients into low, intermediate, high, and very high risk of late sustained VAs.
Experts Achieve Consensus on a Majority of Statements Regarding Ethics, Transparency, Regulation, and Best Practices for the Use of Orthobiologics
Gilat, Ron , Muth, Sarah A. , Hurley, Eoghan T. , Yazdi, Allen A. , Franzia, Chloe H, Shapiro, Shane A. , Cole, Brian J. , Shapiro, Shane , Franzia, Chloe H., Rodeo, Scott A. , Frank, Rachel M , Kon, Elizaveta

Mayo Clinic

Arthroscopy | February 10, 2025 | Volume: 41 | Issue: 9 | Pages: 3611-3621

10.1016/j.arthro.2025.01.062 | PMID 39938667 Get It

Purpose To establish consensus statements via a modified Delphi process about ethics, transparency, regulation, and best practices for the use of orthobiologics in clinical practice for musculoskeletal pathology. Methods A consensus process on the regulation of orthobiologics at the provider level was conducted using a modified Delphi technique. Twenty orthopaedic surgeons, sports medicine physicians, or basic scientists participated. Each participant was a Biologic Association member organization representative and asked to participate because of their active interest in the field of orthobiologics. Levels of consensus were delineated according to the number of votes for each statement: no consensus, <80%; consensus, 80% to 89%; strong consensus, 90% to 99%; unanimous, 100%. Results The 26 consensus statements on orthobiologics resulted in 14 achieving unanimous consensus, 8 achieving strong consensus, 3 achieving consensus, and 1 did not achieve consensus. Overall, 85% of the statements reached either a unanimous or strong consensus. Of the statements regarding communication and transparency, 9 reached unanimous consensus, including information to convey and helpful tools to describe current orthobiologics, persistent misinformation, use of the word “stem cells,” “off‐label” use, and problems with the present regulatory environment. Five statements discussing the regulation of novel orthobiologics achieved unanimous consensus. These statements highlighted research regulation, safety, and suggested improvements to regulatory issues. The statement that did not achieve any consensus was on the regulatory processes that should be in place by an institution providing novel orthobiologic treatments. No statement reached a unanimous agreement on cost or ethical considerations. Conclusions This study successfully identified key consensus statements emphasizing the importance of ethics, transparency, and regulation in the use of orthobiologics, with 85% of statements reaching unanimous or strong consensus. These findings underscore the need for standardized communication, improved regulatory frameworks, and enhanced safety measures while highlighting persistent challenges in addressing cost and ethical considerations. Level of Evidence Level V, expert opinion.
Progressive Myelitis in a 63-Year-Old Woman
DiMauro, Kimberly A. , Heber, Morgan , Lee, Jonathan , Cohen, Jeffrey A. , Riley, Claire , Goldman, Myla , Zamvil, Scott S. , Kunchok, Amy , Flanagan, E P , Riley, Claire , Goldman, Myla D , Zamvil, Scott S , Pittock, Sean J , Cohen, Jeffrey Allen , Flanagan, Eoin P.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | February 10, 2025 | Volume: 12 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000200382 | PMID 39928908 Get It

Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study
Kamel, Moaz, Mahmoud, Ahmed , Badr, Amro , Pereyra, Milagros , Scalia, Isabel G. , Ali, Nima Baba , Alsidawi, Said , Lester, Steven J., Rmilah, Anan Abu, Barry, Timothy, Shen, Win K., Scott, Luis R. , Masry, Hicham El , Valverde, Arturo M. , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , Mahmoud, Ahmed K , Pereyra Pietri, Milagros, Alsidawi, Said , Sardana, Mayank , Sorajja, Dan , Ayoub, Chadi , Arsanjani, Reza , El Masry, Hicham , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Rmilah, Anan Abu , Srivathsan, Komandoor

Mayo Clinic

European Journal of Preventive Cardiology | February 7, 2025 | Volume: 32 | Issue: 9 | Pages: 769-777

10.1093/eurjpc/zwaf063 | PMID 39919039 Get It

Abstract Aims Atrial fibrillation (AF) is the most common cardiac arrhythmia. Although lipoprotein(a) [Lp(a)] is known to be a well-established risk factor for atherosclerotic cardiovascular disease, its role in the development of AF, independent of this association, remains unclear. Methods and results Adult patients from the three Mayo Clinic sites with a baseline Lp(a) and without AF history were included. Patients were categorized into two groups based on their Lp(a) levels: high Lp(a) (≥50 mg/dL) and low Lp(a) (&lt;50 mg/dL). Survival probabilities free from incident AF were compared between Lp(a) groups, during a follow-up period up to 15 years, using the Kaplan–Meier curve and the log-rank test. Multivariable Cox regression analysis was also conducted. A total of 75 376 patients were included (median age: 55 years, 59% males), with a median follow-up duration of 8.8 (inter-quartile range: 3.4, 14.8) years. Incident AF was detected in 5738 (7.6%) patients. Survival probability free from incident AF was significantly lower in patients with elevated Lp(a) (86%) compared with those with low Lp(a) (88%, log-rank P &lt; 0.001). Multivariable analysis adjusted for potential risk factors of AF showed a statistically significant association of elevated Lp(a) with an 11% increase in AF risk (adjusted hazard ratio: 1.11, 95% confidence interval: 1.05–1.18). Conclusion Our study suggests that elevated Lp(a) (≥50 mg/dL) is an independent risk factor for incident AF. Future prospective studies are warranted to validate our results and to test if reducing Lp(a) could mitigate the burden of AF.